194 related articles for article (PubMed ID: 9803139)
1. Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide.
Peters FP; Braat SH; Heymeriks J; Wellens HJ
Neth J Med; 1998 Sep; 53(3):93-6. PubMed ID: 9803139
[TBL] [Abstract][Full Text] [Related]
2. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation.
Reisinger J; Gatterer E; Heinze G; Wiesinger K; Zeindlhofer E; Gattermeier M; Poelzl G; Kratzer H; Ebner A; Hohenwallner W; Lenz K; Slany J; Kuhn P
Am J Cardiol; 1998 Jun; 81(12):1450-4. PubMed ID: 9645896
[TBL] [Abstract][Full Text] [Related]
3. Atrial fibrillation: rate control often better than rhythm control.
Prescrire Int; 2004 Apr; 13(70):64-9. PubMed ID: 15148984
[TBL] [Abstract][Full Text] [Related]
4. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
Crijns HJ; Van Gelder IC; Van Gilst WH; Hillege H; Gosselink AM; Lie KI
Am J Cardiol; 1991 Aug; 68(4):335-41. PubMed ID: 1907089
[TBL] [Abstract][Full Text] [Related]
5. The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation.
Frick M; Darpö B; Ostergren J; Rosenqvist M
Eur Heart J; 2000 Jul; 21(14):1177-85. PubMed ID: 10924301
[TBL] [Abstract][Full Text] [Related]
6. Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation.
Kirchhof P; Engelen M; Franz MR; Ribbing M; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
Basic Res Cardiol; 2005 Mar; 100(2):112-21. PubMed ID: 15696400
[TBL] [Abstract][Full Text] [Related]
7. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
[TBL] [Abstract][Full Text] [Related]
8. Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation.
Climent VE; Marin F; Mainar L; Gomez-Aldaravi R; Martinez JG; Chorro FJ; Roman P; Sogorb F
Pacing Clin Electrophysiol; 2004 Mar; 27(3):368-72. PubMed ID: 15009866
[TBL] [Abstract][Full Text] [Related]
9. Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: assessment of the electrophysiological effects by biatrial basket electrodes.
Lai LP; Lin JL; Lien WP; Tseng YZ; Huang SK
J Am Coll Cardiol; 2000 May; 35(6):1434-41. PubMed ID: 10807444
[TBL] [Abstract][Full Text] [Related]
10. Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial.
Thomas SP; Guy D; Wallace E; Crampton R; Kijvanit P; Eipper V; Ross DL; Cooper MJ
Am Heart J; 2004 Jan; 147(1):E3. PubMed ID: 14691441
[TBL] [Abstract][Full Text] [Related]
11. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation.
Pohjantähti-Maaroos H; Hyppölä H; Lekkala M; Sinisalo E; Heikkola A; Hartikainen J
Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):114-120. PubMed ID: 28849946
[TBL] [Abstract][Full Text] [Related]
12. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens.
Crijns HJ; van Wijk LM; van Gilst WH; Kingma JH; van Gelder IC; Lie KI
Eur Heart J; 1988 Jun; 9(6):634-8. PubMed ID: 3137061
[TBL] [Abstract][Full Text] [Related]
13. Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation.
Nergärdh A; Nordlander R; Frick M
Clin Cardiol; 2006 Feb; 29(2):56-60. PubMed ID: 16506639
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol.
Wijffels MC; Dorland R; Allessie MA
J Cardiovasc Electrophysiol; 1999 Feb; 10(2):178-93. PubMed ID: 10090222
[TBL] [Abstract][Full Text] [Related]
15. Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation.
Boriani G; Biffi M; Capucci A; Bronzetti G; Ayers GM; Zannoli R; Branzi A; Magnani B
J Am Coll Cardiol; 1999 Feb; 33(2):333-41. PubMed ID: 9973012
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic performances in patients treated with sotalol after electrical cardioversion of atrial fibrillation.
Dan GA; Gonţa A
Rom J Intern Med; 1997; 35(1-4):19-27. PubMed ID: 9562649
[TBL] [Abstract][Full Text] [Related]
17. [Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs].
Viñolas X; Freire F; Romero-Menor C; Alegret JM
Med Clin (Barc); 2013 Apr; 140(8):351-5. PubMed ID: 22982132
[TBL] [Abstract][Full Text] [Related]
18. Ibutilide in persistent atrial fibrillation refractory to conventional cardioversion methods.
Naegeli B; Straumann E; Bertel O
Int J Cardiol; 2005 Mar; 99(2):283-7. PubMed ID: 15749188
[TBL] [Abstract][Full Text] [Related]
19. Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study.
Er F; Aslan O; Caglayan E; Gassanov N; Nia AM; Erdmann E; Rosenkranz S
Clin Res Cardiol; 2010 Jun; 99(6):369-73. PubMed ID: 20180126
[TBL] [Abstract][Full Text] [Related]
20. Oral antiarrhythmic drugs in converting recent onset atrial fibrillation.
Deneer VH; Borgh MB; Kingma JH; Lie-A-Huen L; Brouwers JR
Pharm World Sci; 2004 Apr; 26(2):66-78. PubMed ID: 15085940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
